
Sable Bio is an innovative biotechnology company that leverages artificial intelligence to enhance drug safety assessments. Their platform, Sable Target Intelligence, provides a comprehensive and systematic approach to toxicology, enabling researchers to prioritize and mitigate risks effectively. With a focus on user-friendly tools and relevant scientific evidence, Sable aims to accelerate the development of safe and effective medicines. The company has established partnerships within the pharmaceutical industry and is backed by visionary investors, positioning itself as a leader in the evolving landscape of drug safety.

Sable Bio is an innovative biotechnology company that leverages artificial intelligence to enhance drug safety assessments. Their platform, Sable Target Intelligence, provides a comprehensive and systematic approach to toxicology, enabling researchers to prioritize and mitigate risks effectively. With a focus on user-friendly tools and relevant scientific evidence, Sable aims to accelerate the development of safe and effective medicines. The company has established partnerships within the pharmaceutical industry and is backed by visionary investors, positioning itself as a leader in the evolving landscape of drug safety.
Product: Sable Target Intelligence — AI platform for drug target safety and toxicology assessments
Founders: Dr. Josh Almond-Thynne and Dr. Alex de Giorgio
Location: London (Runway East Aldgate)
Recent funding: ~£1.5M pre-seed announced Jan–Feb 2024
Drug target toxicology and safety assessment
2023
Biotechnology
£1.5M (reported)
Round announced in late Jan–early Feb 2024; reporting cites ~£1.5M and participation from Seedcamp and individual investors
“Backed by early-stage investors including Episode One, Seedcamp, and MMC Ventures”